Press release

Optime Care Offers Patient-First Humatin Total Care Program, Maximizes Therapeutic Benefits of Humatin™ for Treatment of Intestinal Amebiasis

Sponsored by Businesswire

Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin™ (paromomycin sulfate) exclusively through Humatin Total Care. This patient-first drug management program optimizes the benefits of Humatin for patients with acute and chronic intestinal amebiasis. Download the provider toolkit here.

“Physicians play an important role in educating their patients about the disease, symptoms and the benefits of Humatin, which is why we work with them to help maximize the therapeutic opportunity for treating intestinal amebiasis,” says Donovan Quill, president and CEO, Optime Care. “For the patients, our dedicated Humatin Total Care coordinator works with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery.”

People become infected with intestinal amebiasis by ingesting contaminated food or water, or cysts (eggs) through contact with fecal matter of a person infected with the protozoan. Of those infected, approximately 10-20% become sick.

Intestinal amebiasis is a parasitic infection of the intestines caused by a protozoan E. histolytica that can affect anyone, although it is more common in people who live in or who have traveled to tropical areas with poor sanitary conditions. Symptoms include loose stool, stomach pain and abdominal cramping, which usually develop within 2-4 weeks and are generally mild.

Quill concludes, “Humatin Total Care exemplifies how our patient-first focus helps every stakeholder group impacted by this disease.”

To schedule a lunch and learn, contact Humatin Total Care Team at 1-844-486-2846.

About Optime Care

Optime Care, Inc. is a nationally recognized pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders. Our management team has previously partnered in the launch and management of more than 40 orphan products and programs and consistently implemented the best brand programs for the community. Our experience with small patient populations makes us uniquely qualified to help every stakeholder group impacted by these disorders. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers.